Cargando…

COVID‐19: vaccine’s progress

Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over...

Descripción completa

Detalles Bibliográficos
Autor principal: Brüssow, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209887/
https://www.ncbi.nlm.nih.gov/pubmed/33960659
http://dx.doi.org/10.1111/1751-7915.13818
_version_ 1783709212407234560
author Brüssow, Harald
author_facet Brüssow, Harald
author_sort Brüssow, Harald
collection PubMed
description Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus‐vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts.
format Online
Article
Text
id pubmed-8209887
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82098872021-06-21 COVID‐19: vaccine’s progress Brüssow, Harald Microb Biotechnol Lilliput Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus‐vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts. John Wiley and Sons Inc. 2021-05-07 /pmc/articles/PMC8209887/ /pubmed/33960659 http://dx.doi.org/10.1111/1751-7915.13818 Text en © 2021 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Lilliput
Brüssow, Harald
COVID‐19: vaccine’s progress
title COVID‐19: vaccine’s progress
title_full COVID‐19: vaccine’s progress
title_fullStr COVID‐19: vaccine’s progress
title_full_unstemmed COVID‐19: vaccine’s progress
title_short COVID‐19: vaccine’s progress
title_sort covid‐19: vaccine’s progress
topic Lilliput
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209887/
https://www.ncbi.nlm.nih.gov/pubmed/33960659
http://dx.doi.org/10.1111/1751-7915.13818
work_keys_str_mv AT brussowharald covid19vaccinesprogress